In 2019 a flavonoid of cannabis – Caflanone (FBL-03G) – was granted Orphan drug status by the United States Food and Drug Administration. Now, trials using the flavonoid to treat pancreatic cancer are anticipated to begin in the spring.
Flavocure, a drug discovery and development company, was granted Orphan drug status to its lead drug candidate, the cannabis flavonoid Caflanone (FBL-03G), by the United States Food and Drug Administration (FDA), following the successful demonstration of its therapeutic efficacy in tumour progression in animals with pancreatic cancer.
The company is now on track to begin clinical trials for treating pancreatic cancer with Caflanone in the spring.
Click here to read the complete article
Health Europa ~